Eli Lilly's Taltz-Zepbound combo scores in late-stage PsA study [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
During the Phase IIIb TOGETHER-PsA study (NCT06588296), the concomitant use of Zepbound-Taltz significantly increased the percentage of patients (31.7%) exhibiting at least a 50% improvement in psoriatic arthritis (PsA) activity and a 10% reduction in body weight compared with Taltz alone (0.8%) – meeting its primary endpoint. Measures of PsA activity were categorised through the American College of Rheumatology 50 (ACR50) system, which is used to determine if a patient with PsA has had a clinically significant response to a disease-modifying therapy (DMT) such as Taltz. The trial also met its secondary endpoint, as Taltz-Zepbound prompted an ACR50 response in 33.5% of patients – a 64% relative increase over the 20.4% who achieved this milestone in the Taltz monotherapy group. This suggests that the drugs can work in synergy to reduce PsA activity. Treatment-emergent adverse events (TEAEs) associated with Zepbound-Taltz also aligned with the respective safety profile of each th
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredients [FOX News]FOX News
- This Healthcare Stock Could Be One of the Best Companies to Own in 2026 [Yahoo! Finance]Yahoo! Finance
- Can Eli Lilly and Company's (NYSE:LLY) ROE Continue To Surpass The Industry Average? [Yahoo! Finance]Yahoo! Finance
- Aktis Oncology Jumps 27% After $318 Million Upsized IPO [Yahoo! Finance]Yahoo! Finance
- Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public MarketsBusiness Wire
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- LLY's page on the SEC website